Replies to post #5489 on Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

TC- per usual, carb issued misleading/incorrect info

"Canaccord Genuity assumes coverage on Aurinia Pharmaceuticals (NASDAQ: AUPH) with a Spec. Buy rating and a price target of $10.00.

Analyst Neil Maruoka says the company is exposed to the high risks that come with biotech drug development. The analyst believes the company's AURORA drug has a good chance of success (65%) which is "higher than historically seen in other Phase III trials for autoimmune disease." Maruoka also sees the company as an attractive candidate for partnering noting "its positioning as an add-on therapy and potential synergy with the current standard of care, we believe voclosporin represents an attractive partnering opportunity."

https://www.streetinsider.com/Analyst+Comments/Canaccord+Genuity+Assumes+Aurinia+Pharmaceuticals+%28AUPH%29+at+Spec.+Buy%2C+Sees+Co.+As+Attractive+Partnering+Candidate/13290384.html